Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes A randomized, control, open-labeled trial

Medicine (United States)

Volumn 95, Issue 43, 2016, Pages

  Li, Feng Fei ^a   Jiang, Lan Lan ^a   Yan, Reng Na ^a   Zhu, Hong Hong ^a   Zhou, Pei Hua ^a   Zhang, Dan Feng ^a   Su, Xiao Fei ^a   Wu, Jin Dan ^a   Ye, Lei ^b   Ma, Jian Hua ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b DEPARTMENT OF CARDIOLOGY   (Singapore)

Author keywords

Add on therapy; Blood glycemic fluctuation; Saxagliptin; Type 2 diabetes

Indexed keywords

ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; INSULIN; SAXAGLIPTIN;

ADOLESCENT; ADULT; AGED; ANALOGS AND DERIVATIVES; BLOOD; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG EFFECTS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADAMANTANE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAMUSCULAR; INSULIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84995972804     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000005229     Document Type: Article

References (37)

1. Retnakaran R, Drucker DJ. Intensive insulin therapy in newly diagnosed type 2 diabetes. Lancet 2008;371:1725-6.
2. Ilkova H, Glaser B, Tunckale A, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997;20:1353-6.
3. Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004;27:2597-602.
4. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004;27:1028-32.
5. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371:1753-60.
6. Li FF, Fu LY, Zhang WL, et al. Blood glucose fluctuations in type 2 diabetes patients treated with multiple daily injections. J Diabetes Res 2016;2016:1028945.
7. Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-40.
8. DECODE Study Group. European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405.
9. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-25.
10. Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004;47:385-94.
11. Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:5025-37.
12. Dhillon S, Weber J. Saxagliptin. Drugs 2009;69:2103-14.
13. Frederich R, McNeill R, Berglind N, et al. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetol Metab Syndr 2012;4:36.
14. Pan CY, Yang W, Tou C, et al. Efficacy and safety of saxagliptin in drugnaive Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev 2012;28:268-75.
15. Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2009;25:2401-11.
16. Jain R. Utility of saxagliptin in the treatment of type 2 diabetes: review of efficacy and safety. Adv Ther 2015;32:1065-84.
17. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-55.
18. Hermans MP, Delibasi T, Farmer I, et al. Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study. Curr Med Res Opin 2012;28:1635-45.
19. Yang W, Pan CY, Tou C, et al. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Res Clin Pract 2011;94:217-24.
20. Barnett AH, Charbonnel B, Donovan M, et al. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin 2012;28:513-23.
21. Xiaoyan C, Jing W, Xiaochun H, et al. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea. Curr Med Res Opin 2016;32:1131-6.
22. Henry RR, Smith SR, Schwartz SL, et al. Effects of saxagliptin on betacell stimulation and insulin secretion in patients with type 2 diabetes. Diabetes Obes Metab 2011;13:850-8.
23. Rohrborn D, Bruckner J, Sell H, et al. Reduced DPP4 activity improves insulin signaling in primary human adipocytes. Biochem Biophys Res Commun 2016;471:348-54.
24. Ziegler R, Tubili C, Chico A, et al. ProAct study: new features of insulin pumps improve diabetes management and glycemic control in patients after transition of continuous subcutaneous insulin infusion systems. Diabetes Technol Ther 2013;15:738-43.
25. Li FF, Xu XH, Fu LY, et al. Influence of acarbose on plasma glucose fluctuations in insulin-treated patients with type 2 diabetes: a pilot study. Int J Endocrinol 2015;2015:903524.
26. Schnell O, Mertes G, Standl E. Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy. Diabetes Obes Metab 2007;9:853-8.
27. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006;60:1454-70.
28. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24-32.
29. Cahn A, Raz I, Mosenzon O, et al. Predisposing factors for any and major hypoglycemia with saxagliptin versus placebo and overall: analysis from the SAVOR-TIMI 53 trial. Diabetes Care 2016;39: 1329-37.
30. Toh S, Hampp C, Reichman ME, et al. Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study. Ann Intern Med 2016;164: 705-14.
31. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-7.
32. Ceriello A, Quagliaro L, Catone B, et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 2002;25:1439-43.
33. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
34. Charbonnel B, Cariou B. Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. Diabetes Obes Metab 2011;13:99-117.
35. Barnett AH, Cradock S, Fisher M, et al. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Int J Clin Pract 2010;64:1121-9.
36. Chen W, Jiang H, Tao YX, et al. [Development and interpretation of China medical nutrition therapy guideline for diabetes (2010)]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2011;33:253-6.
37. Lu QG, Tong NW. Interpretation of Chinese Society of Endocrinology consensus statement on hyperglycemia management target in adult inpatients in China. J Diabetes 2013;5:416-20.